BD (Becton, Dickinson and Company) announced strong financial results for its fiscal 2024 fourth quarter and full year, which ended September 30, 2024. For Q4 FY24, total revenues reached $5.437 billion, marking a 6.9% increase as reported and 6.2% organic growth year-over-year, surpassing analysts' expectations.
Adjusted diluted earnings per share from continuing operations for the fourth quarter were $3.81, an 11.4% increase from the prior-year period. This performance was driven by strong operational execution and margin expansion, particularly in the BD Medical segment, which saw 8.6% organic revenue growth led by Medication Management Solutions.
For fiscal year 2025, BD provided guidance projecting GAAP revenue growth of 8.9% to 9.4%, with total revenues expected between $21.9 billion and $22.1 billion. Organic revenue growth is forecast at 4.0% to 4.5%, despite an anticipated 125 basis point impact from declines in China and Bioscience and Pharma market dynamics. Adjusted diluted EPS is projected to be between $14.25 and $14.60, representing 8.5% to 11.0% growth at the midpoint.
The company's Board of Directors also declared a quarterly dividend of $1.04 per common share, representing a 9.5% increase from the previous quarter. This marks the 53rd consecutive fiscal year of dividend increases, maintaining BD's position in the S&P 500 Dividend Aristocrats Index and reflecting confidence in its long-term outlook and commitment to shareholder returns.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.